{"id":5663,"date":"2017-03-09T20:53:36","date_gmt":"2017-03-10T01:53:36","guid":{"rendered":"http:\/\/localhost:10028\/practiceareas\/onglyza\/"},"modified":"2022-06-21T16:54:03","modified_gmt":"2022-06-21T20:54:03","slug":"onglyza","status":"publish","type":"practiceareas","link":"https:\/\/napolilaw.lemonadestand.org\/tr\/uygulama-alanlari-2\/onglyza\/","title":{"rendered":"onglyza"},"content":{"rendered":"<p>Tip II diyabet tedavisi i\u00e7in ilk olarak 2009 y\u0131l\u0131nda FDA taraf\u0131ndan onaylanan Onglyza, saksagliptin aktif maddesi, pop\u00fcler bir re\u00e7eteli ila\u00e7t\u0131r. Onglyza, karaci\u011ferin fazla \u015feker olu\u015fturmas\u0131n\u0131 \u00f6nleyerek ve pankreas\u0131n ins\u00fclin salg\u0131lamas\u0131na yard\u0131mc\u0131 olarak \u00e7al\u0131\u015f\u0131r. Onglyza ve di\u011fer DPP-4 inhibit\u00f6rleri, ABD genelinde hastalar ve doktorlar aras\u0131nda favori olmas\u0131na ra\u011fmen tehlikeli yan etkilere sahiptir.<\/p>\n<p>&nbsp;<\/p>\n<h3>Onglyza Almakla \u0130li\u015fkili Riskler<\/h3>\n<p>Mevcut G\u0131da ve \u0130la\u00e7 \u0130daresi <a href=\"http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM280356.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">ila\u00e7 rehberi<\/a> Onglyza i\u00e7in, Onglyza alman\u0131n pankreatite (pankreas iltihab\u0131) yol a\u00e7abilece\u011fine dair bir uyar\u0131 vard\u0131r. Ve 2015 y\u0131l\u0131n\u0131n Nisan ay\u0131nda, <a href=\"http:\/\/www.medscape.com\/viewarticle\/843179\" target=\"_blank\" rel=\"noopener noreferrer\">FDA ayr\u0131ca kalp yetmezli\u011fi riski i\u00e7in bir g\u00fcvenlik uyar\u0131s\u0131 ta\u015f\u0131yan Onglyza&#039;y\u0131 destekledi.<\/a> Onglyza alanlar\u0131n kalp yetmezli\u011fi riskinin y\u00fczde 27 daha fazla oldu\u011fu bulgusuna dayanmaktad\u0131r. Pankreatit ve kalp yetmezli\u011fine ek olarak, Onglyza alman\u0131n bir ba\u015fka ciddi yan etkisi de pankreas kanseridir.<\/p>\n<p>&nbsp;<\/p>\n<h3>Onglyza&#039;n\u0131n Yap\u0131c\u0131s\u0131na Kar\u015f\u0131 A\u00e7\u0131lan Davalar<\/h3>\n<p>Pek \u00e7ok ki\u015fi, pankreas kanseri, pankreatit ve kalp yetmezli\u011fi ile ili\u015fkili riskleri bilmeden Onglyza&#039;y\u0131 ald\u0131\u011f\u0131 ve bunun sonucunda zarar g\u00f6rd\u00fc\u011f\u00fc i\u00e7in, bir\u00e7o\u011fu do\u011frudan Onglyza&#039;n\u0131n \u00fcreticisi AstraZeneca&#039;ya kar\u015f\u0131 dava a\u00e7may\u0131 se\u00e7ti. Bu davalar, Onglyza&#039;n\u0131n ilac\u0131 piyasaya s\u00fcrmeden \u00f6nce uygun g\u00fcvenlik testleri yapmad\u0131\u011f\u0131n\u0131 ve\/veya ilac\u0131n riskleri konusunda yeterince uyar\u0131da bulunmad\u0131\u011f\u0131n\u0131 iddia etmektedir.<\/p>\n<p>&nbsp;<\/p>\n<h3>Neden Kusurlu Bir \u0130la\u00e7 Vekiline \u0130htiyac\u0131n\u0131z Var?<\/h3>\n<p>Filing a lawsuit against the maker of a defective drug can yield damages for pain and suffering, medical expenses, lost wages, and other economic and noneconomic losses. But filing a lawsuit against a large pharmaceutical company can be complicated, and without a legal professional on your side, the chances of making a costly error are high.<\/p>\n<p>To improve your chances of recovering your full damages amount in a civil action against AstraZeneca, you need the representation of the experienced <a href=\"\/tr\/uygulama-alanlari-2\/ilac-davasi\/\">ila\u00e7 dava avukatlar\u0131<\/a> Napoli Shkolnik, PLLC&#039;da \u00e7al\u0131\u015f\u0131yor Hak talebinde bulunma hakk\u0131n\u0131z hakk\u0131nda daha fazla bilgi edinmek i\u00e7in bug\u00fcn bizi aray\u0131n ve ilk dan\u0131\u015fma randevunuzu planlay\u0131n.<\/p>","protected":false},"excerpt":{"rendered":"<p>Tip II diyabet tedavisi i\u00e7in ilk olarak 2009 y\u0131l\u0131nda FDA taraf\u0131ndan onaylanan Onglyza, saksagliptin aktif maddesi, pop\u00fcler bir re\u00e7eteli ila\u00e7t\u0131r. Onglyza, karaci\u011feri \u00f6nleyerek \u00e7al\u0131\u015f\u0131r\u2026<\/p>","protected":false},"featured_media":0,"menu_order":182,"template":"","practiceareas_category":[743],"class_list":["post-5663","practiceareas","type-practiceareas","status-publish","hentry","practiceareas_category-pharmaceutical-litigation"],"acf":[],"_links":{"self":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/practiceareas\/5663","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/practiceareas"}],"about":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/types\/practiceareas"}],"version-history":[{"count":0,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/practiceareas\/5663\/revisions"}],"wp:attachment":[{"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/media?parent=5663"}],"wp:term":[{"taxonomy":"practiceareas_category","embeddable":true,"href":"https:\/\/napolilaw.lemonadestand.org\/tr\/wp-json\/wp\/v2\/practiceareas_category?post=5663"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}